Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

2024年03月11日 22:28:34

打印 放大 缩小

Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term extension (LTE) study show that more than 80% of nemolizumab-treated patients with prurigo nodularis experienced improvement in itch and more than 60% achieved clear or almost-clear skin1
Results from the phase III ARCADIA clinical trials in atopic dermatitis show that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks2
These new data build on results from the phase III OLYMPIA and ARCADIA clinical trial programs and demonstrate nemolizumab’s long-term and long-lasting benefit in prurigo nodularis and atopic dermatitis, respectively1-5

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).2 These late-breaking data are being presented today at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.

 

“We’re excited to see the evidence base for nemolizumab continue to
build and strengthen for these debilitating diseases, where symptoms
such as intense itch can put a significant burden on quality of life.
Having already demonstrated nemolizumab’s efficacy and rapid onset
of action, these new results show its long-term benefit and durability of
response in prurigo nodularis and atopic dermatitis, respectively.”

 

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA

 

 

责任编辑:admin

相关阅读

百度网友:你就如此不堪
评论:他看事总乐观,看人总悲观!

天涯网友:想哭卻無淚
评论:我一直在希望的田野上奔跑,虽然也偶尔被失望绊倒。

淘宝网友:時間不會等待
评论:把你的样子当成黑白照,裱个相框供在心里,想你了,就烧几柱香。

搜狐网友:ヾ荆棘里的花
评论:什么是兄弟?兄弟就是50年后你老了躺在床上,我问你喝水不?你摇头。吃水果不?你还是摇头。我再问:给你找个妞?你睁大眼睛,眼里闪着泪花。兄弟,扶我起来试试。。。

天猫网友:若凌° Provence -
评论:女人最恨的男人是陈世美;男人最喜欢的女人是潘金莲。

本网网友:pome 光感
评论:最美好的是爱情,最理解的是友情,最真诚的是亲情。

凤凰网友:゛风骚, - /ov3
评论:小时候哭着哭着就笑了,长大后笑着笑着就哭了。

猫扑网友:总算我们也爱过
评论:我是一个很有原则的人,我的原则只有三个字,看心情

网易网友:㏒° 煽情mmmm
评论:“高富帅官二代”这六个字,我想我只做到了第五个字。

腾讯网友:冷眸2  Cruel
评论:木纳这事,如果干的好,叫深沉